Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Cash from Operations for 4 consecutive years, with 1240696.0 as the latest value for Q4 2020.

  • Quarterly Cash from Operations fell 85.54% to 1240696.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was 4662274.0 through Dec 2020, down 54.5% year-over-year, with the annual reading at 12201291.0 for FY2025, 90.52% down from the prior year.
  • Cash from Operations hit 1240696.0 in Q4 2020 for Monopar Therapeutics, up from 1300534.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 305128.0 in Q2 2017 to a low of 1300534.0 in Q3 2020.
  • Historically, Cash from Operations has averaged 811744.31 across 4 years, with a median of 780856.0 in 2018.
  • Biggest YoY gain for Cash from Operations was 49.82% in 2018; the steepest drop was 159.67% in 2018.
  • Year by year, Cash from Operations stood at 816021.0 in 2017, then soared by 36.37% to 519212.0 in 2018, then fell by 28.79% to 668705.0 in 2019, then plummeted by 85.54% to 1240696.0 in 2020.
  • Business Quant data shows Cash from Operations for MNPR at 1240696.0 in Q4 2020, 1300534.0 in Q3 2020, and 995474.0 in Q2 2020.